Use of Novel Small-Molecule PP2A Activators in Prostate Cancer Cell Lines – UROP Spring Symposium 2021

Use of Novel Small-Molecule PP2A Activators in Prostate Cancer Cell Lines

Miranda Giambi

Miranda Giambi

Pronouns: she/her

Research Mentor(s): Goutham Narla, Chief, Division of Genetic Medicine and Associate Professor
Research Mentor School/College/Department: Internal Medicine: Division of Genetic Medicine, Michigan Medicine
Presentation Date: Thursday, April 22, 2021
Session: Session 3 (1pm-1:50pm)
Breakout Room: Room 11
Presenter: 6

Event Link

Abstract

Dysregulation of kinases and phosphatases in the signal-transduction-pathway disrupts cellular homeostasis and can result in serious diseases and a variety of cancers. The dysregulation of phosphatases in cancer have received little attention by the scientific community and thus additional knowledge of their role in carcinogenesis is needed to better understand cancer progression and to explore their potential as drug targets (Leonard, 2020). Specifically, I have been helping two staff scientists in the Narla lab study the post-translational modifications of protein-phosphatase PP2A in prostate cancer using molecular biology assays and to test novel small-molecule PP2A activators the Narla lab is developing. These novel small-molecule PP2A activators are expected to prompt downregulation of oncogenic transcription factors and modulate post-translational changes.

Authors: Miranda Giambi, Goutham Narla
Research Method: Laboratory Research

lsa logoum logo